Aura Biosciences, Inc. Operating Income
Aura Biosciences, Inc. (AURA) reported Operating Income of -$48.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- Aura Biosciences, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$48.07M.
- Aura Biosciences, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$34.87M.
- Aura Biosciences, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$27.24M.
- Aura Biosciences, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$27.91M.
- Aura Biosciences, Inc. operating income (loss) for fiscal 2025 was -$112.79M.
- Aura Biosciences, Inc. operating income (loss) for fiscal 2024 was -$96.12M.
- Aura Biosciences, Inc. operating income (loss) for fiscal 2023 was -$84.99M.
- Aura Biosciences, Inc. operating income (loss) for fiscal 2022 was -$60.30M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$48.07M 10-Q · filed 2026-08-11 | -$82.94M 10-Q · filed 2026-08-11 | -$110.17M derived: sum of 3 quarters · filed 2026-08-11 | -$138.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$34.87M 10-Q · filed 2026-05-11 | -$62.10M derived: sum of 2 quarters · filed 2026-05-11 | -$90.01M derived: sum of 3 quarters · filed 2026-05-11 | -$118.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$27.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$55.14M derived: sum of 2 quarters · filed 2026-03-30 | -$83.76M derived: sum of 3 quarters · filed 2026-08-11 | -$112.79M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$27.91M 10-Q · filed 2025-11-13 | -$56.52M derived: sum of 2 quarters · filed 2026-08-11 | -$85.55M 10-Q · filed 2025-11-13 | -$113.36M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$28.61M 10-Q · filed 2026-08-11 | -$57.65M 10-Q · filed 2026-08-11 | -$85.45M derived: sum of 3 quarters · filed 2026-08-11 | -$108.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$29.04M 10-Q · filed 2026-05-11 | -$56.84M derived: sum of 2 quarters · filed 2026-05-11 | -$80.07M derived: sum of 3 quarters · filed 2026-05-11 | -$102.84M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$27.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$51.04M derived: sum of 2 quarters · filed 2026-03-30 | -$73.80M derived: sum of 3 quarters · filed 2026-03-30 | -$96.12M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$23.23M 10-Q · filed 2025-11-13 | -$45.99M derived: sum of 2 quarters · filed 2025-11-13 | -$68.31M 10-Q · filed 2025-11-13 | -$93.09M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$22.76M 10-Q · filed 2025-08-13 | -$45.08M 10-Q · filed 2025-08-13 | -$69.86M derived: sum of 3 quarters · filed 2025-08-13 | -$90.35M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$22.31M 10-Q · filed 2025-05-15 | -$47.10M derived: sum of 2 quarters · filed 2025-05-15 | -$67.58M derived: sum of 3 quarters · filed 2025-05-15 | -$87.86M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$24.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$45.27M derived: sum of 2 quarters · filed 2025-03-24 | -$65.55M derived: sum of 3 quarters · filed 2025-03-24 | -$84.99M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$20.49M 10-Q · filed 2024-11-12 | -$40.76M derived: sum of 2 quarters · filed 2024-11-12 | -$60.21M 10-Q · filed 2024-11-12 | -$77.82M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$20.28M 10-Q · filed 2024-08-08 | -$39.72M 10-Q · filed 2024-08-08 | -$57.33M derived: sum of 3 quarters · filed 2024-08-08 | -$73.39M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$19.44M 10-Q · filed 2024-05-09 | -$37.06M derived: sum of 2 quarters · filed 2024-05-09 | -$53.11M derived: sum of 3 quarters · filed 2024-05-09 | -$66.93M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$17.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$33.67M derived: sum of 2 quarters · filed 2024-03-27 | -$47.48M derived: sum of 3 quarters · filed 2024-03-27 | -$60.30M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$16.05M 10-Q · filed 2023-11-09 | -$29.87M derived: sum of 2 quarters · filed 2023-11-09 | -$42.68M 10-Q · filed 2023-11-09 | -$54.31M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.82M 10-Q · filed 2023-08-09 | -$26.63M 10-Q · filed 2023-08-09 | -$38.25M derived: sum of 3 quarters · filed 2023-08-09 | -$47.15M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$12.81M 10-Q · filed 2023-05-11 | -$24.44M derived: sum of 2 quarters · filed 2023-05-11 | -$33.33M derived: sum of 3 quarters · filed 2023-05-11 | -$42.13M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$20.52M derived: sum of 2 quarters · filed 2023-03-15 | -$29.32M derived: sum of 3 quarters · filed 2023-03-15 | -$35.25M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$8.89M 10-Q · filed 2022-11-10 | -$17.70M derived: sum of 2 quarters · filed 2022-11-10 | -$23.62M 10-Q · filed 2022-11-10 | -$28.53M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$8.80M 10-Q · filed 2022-08-11 | -$14.73M 10-Q · filed 2022-08-11 | -$19.64M derived: sum of 3 quarters · filed 2022-08-11 | -$23.27M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$5.93M 10-Q · filed 2022-05-12 | -$10.84M derived: sum of 2 quarters · filed 2022-05-12 | -$14.47M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$8.54M derived: sum of 2 quarters · filed 2022-03-23 | -$22.21M 10-K · filed 2022-03-23 | |
| 2020-09-30 | -$3.63M 10-Q · filed 2021-11-24 | -$17.30M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |